Sex Chromosome Dosage Effects on Gene Expression in Humans

Armin Raznahan*[1], Neelroop Parikshak[2], Vijayendran Chandran[2], Jonathan Blumenthal[1], Liv Clasen[1], Aaron Alexander-Bloch[1], Andrew Zinn[3], Danny Wangsa[4], Jasen Wise[5], Declan Murphy[6], Patrick Bolton[6], Thomas Ried[4], Judith Ross[7], Jay Giedd[8], Daniel Geschwind[2]

1. Developmental Neurogenomics Unit, National Institute of Mental Health, NIH, Bethesda, MD, USA
2. Neurogenetics Program, Department of Neurology and Center for Autism Research and Treatment, Semel Institute, David Geffen School of Medicine, University of California Los SCVAngeles, Los Angeles, CA, USA
3. McDermott Center for Human Growth and Development and Department of Internal Medicine, University of Texas Southwestern Medical School, TX, USA
4. Genetics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA
5. Qiagen
6. Institute of Psychiatry, Psychology and Neuroscience, King's College London, University of London, UK
7. Department of Pediatrics, Thomas Jefferson University, Philadelphia, PA, USA
8. Department of Psychiatry, UC San Diego, La Jolla, CA, USA

*Correspondence to: raznahana@mail.nih.gov

ABSTRACT

A fundamental question in the biology of sex-differences has eluded direct study in humans: how does sex chromosome dosage (SCD) shape genome function? To address this, we developed a systematic map of SCD effects on gene function by analyzing genome-wide expression data in humans with diverse sex chromosome aneuploidies (XO, XXX, XXY, XYY, XXYY). For sex chromosomes, we demonstrate a pattern of obligate dosage sensitivity amongst evolutionarily preserved X-Y homologs, and revise prevailing theoretical models for SCD compensation by detecting X-linked genes whose expression increases with decreasing X- and/or Y-chromosome dosage. We further show that SCD-sensitive sex chromosome genes regulate specific co-expression networks of SCD-sensitive autosomal genes with critical cellular functions and a demonstrable potential to mediate previously documented SCD effects on disease. Our findings detail wide-ranging effects of SCD on genome function with implications for human phenotypic variation.

INTRODUCTION

Disparity in SCD is fundamental to the biological definition of sex throughout much of the animal kingdom. In almost all eutherian mammals, females carry two X-chromosomes, while males carry an X- and a Y-chromosome: presence of the Y-linked SRY gene determines a testicular gonadal phenotype, while its absence allows development of ovaries[1]. Sexual differentiation of the gonads leads to hormonal sex-differences that have traditionally been considered the major proximal cause for extra-gonadal phenotypic sex-differences. However, diverse studies, including recent work in transgenic mice that uncouple Y-chromosome and gonadal status, have revealed direct SCD effects on several sex-biased metabolic, immune and neurological phenotypes[2].

These findings - together with reports of widespread transcriptomic differences between pre-implantation XY and XX embryos[3,4] - suggest that SCD has gene regulatory effects independently of gonadal status. However, genome-wide consequences of SCD remain poorly understood, especially in humans, where experimental dissociation of SCD and gonadal status is not possible. Understanding these regulatory effects is critical for clarifying the biological underpinnings of phenotypic sex-differences, and the clinical features of sex chromosome aneuploidy[5] [SCA, e.g. Turner (XO) and Klinefelter (XXY) syndrome], which can both manifest as altered risk for several common autoimmune and neurodevelopmental disorders (e.g. systemic lupus erythematosus and autism spectrum disorders)[6,7]. Here, we explore the genome

wide consequences of SCD through comparative transcriptomic analyses

amongst humans across a range of dosages including typical XX and XY

karyotypes, as well as several rare SCA syndromes associated with 1, 3, 4 or 5

copies of the sex chromosomes. We harness these diverse karyotypes to dissect

the architecture of dosage compensation amongst sex chromosome genes, and

to systematically map the regulatory effects of SCD on autosomal gene

expression in humans.

We examined gene expression profiles in a total of 469 lymphoblastoid

cell lines (LCLs), from (i) a core sample of 68 participants (12 XO, 10 XX, 9 XXX,

10 XY, 8 XXY, 10 XYY, 9 XXYY) yielding for each sample genome-wide

expression data for 19,984 autosomal and 894 sex-chromosome genes using the

Illumina oligonucleotide Beadarray platform (**Methods**), and (ii) an independent

set of validation/replication samples from 401 participants (3 XO, 145 XX, 22

XXX, 146 XY, 34 XXY, 16 XYY, 17 XXYY, 8 XXXY, 10 XXXXY) with quantitative

reverse transcription polymerase chain reaction (qPCR) measures of expression

for genes of interest identified in our core sample (**Table 1, Methods**).

RESULTS

Evolutionarily Preserved X-Y Gametologs Show Extreme Dosage

Sensitivity

To first verify our study design as a tool for probing SCD effects on gene

expression, and to identify core SCD-sensitive genes, we screened all 20,878

genes in our microarray dataset to define which, if any, genes showed a

persistent pattern of significant differential expression (DE) across all unique

pairwise group contrasts involving a disparity in either X- or Y-chromosome

dosage (n=15 and n=16 contrasts respectively, **Fig. 1a**). Disparities in X-

chromosome dosage were always accompanied by statistically significant DE in

4 genes, which were all X-linked: *XIST* (the orchestrator of X-inactivation) and 3

other known genes known to escape X-chromosome inactivation (*PUDP*,

KDM6A, *EIF1AX*)[8]. Similarly, disparities in Y-chromosome dosage always led to

statistically-significant DE in 6 genes, which were all Y-linked: *CYorf15B*, *DDX3Y*,

TMSB4Y, *USP9Y*, *UTY,* and *ZFY*. Observed expression profiles for these 10

genes perfectly segregated all microarray samples by karyotype group (**Fig. 1b**),

and could be robustly replicated and extended in the independent sample of

LCLs from 401 participants with varying SCD (**Supplementary Fig. 1, Methods**).

Strikingly, 8 of the 10 genes showing obligatory SCD sensitivity (excepting

XIST and PUPD) are members of a class of 16 sex-linked genes with homologs

on both the X and Y chromosomes (i.e. 16 X-Y gene pairs, henceforth

gametologs)[9] that are distinguished from other sex-linked genes by (i) their

selective preservation in multiple species across ~300 million years of sex

chromosome evolution to prevent male-female dosage disparity, (ii) the breadth

of their tissue expression from both sex chromosomes; and (iii) their key

regulatory roles in transcription and translation[9,10] (**Fig. 1c**). Broadening our

analysis to all 14 X-Y gametolog pairs present in our microarray data found that

these genes as a group exhibit a heightened degree of SCD-sensitivity that

distinguishes them from other sex-linked genes (**Fig. 1d, Methods**). These

findings provide the strongest evidence to date that the evolutionary

maintenance, broad tissue expressivity and enriched regulatory functions of X-Y

gametologs[10] are indeed accompanied by a distinctive pattern of dosage

sensitivity, which firmly establishes these genes as candidate regulators of SCD

effects on wider genome function.

Figure 1 (next page). Consistent Gene Expression Changes with Altered Sex Chromosome

Dosage. a) Cross table showing all unique pairwise SCD group contrasts within our microarray

dataset, color coded for their involvement of changes in X- and Y-chromosome count. **b)** Two-

dimensional expression heat-map for the 10 genes showing differential expression across all

contrasts that involve disparity in X or Y-chromosome count. Column colors encode SCD group

membership for each sample. Rows detail gene expression across all SCD samples as a log 2

fold-change relative to the mean expression in XY males. **c)** Table providing Gene ID, location,

function and homolog annotations for the 10 genes that showed obligate SCD sensitivity. Eight

genes in this set are members of X-Y gametolog gene pairs. **d)** Density plots showing observed

mean SCD sensitivity of the 14 gametolog genes in our study (red line), vs, distribution (black

line) of 10,000 randomly sampled sets of non-gametolog sex-linked genes of equal size. Results

are provided separately for X- and Y-chromosomes. For both chromosomes, the mean SCD

sensitivity of the gametolog gene set greater is than that of all 10k permuted gene sets.

a

CONTRAST WITH Δ X DOSE
CONTRAST WITH Δ Y DOSE

b

c

Gene_Name (Alias)	Entrez_ID	Chromosome	Probe_Start	Probe_End	Functions	Gametolog_Name (Alias)	Functions
PUDP (HDHD1)	8226	X	6967201	6967250	encodes protein of unknown biological function	-	-
KDM6A (UTX)	7403	X	44970808	44970857	catalyzes the demethylation of tri/dimethylated histone H3	UTY	protein-protein interactions
XIST	7503	X	73040921	73040970	essential for initiation and spread of X inactivation	-	-
EIF1AX	1964	X	20150300	20150326	essential translation initiation factor	EIF1AY	translation initiation

Gene_Name (Alias)	Entrez_ID	Chromosome	Probe_Start	Probe_End	Functions	Gametolog_Name (Alias)	Functions
ZFY	7544	Y	2849596	2849645	transcription factor	ZFX	transcription factor
USP9Y	8287	Y	14971985	14972034	ubiquination	USP9X	ubiquination
DDX3Y	8653	Y	15032184	15032233	RNA and ATP binding, hydrolysis	DDX3X	RNA helicase, transcriptional regulation and translation
UTY	7404	Y	15360382	15360431	protein-protein interactions	KDM6A (UTX)	catalyzes the demethylation of tri/dimethylated histone H3
TMSB4Y (TB4Y)	9087	Y	15817595	15817644	uncharacterized	TMSB4X (TB4X)	actin polymerization, cell proliferation/differentiation
TXLNGY (CYorf15B)	84663	Y	21765838	21765887	pseudogene	TXLNG	transcriptional regulation, intracellular trafficking

d

113
114
115

Observed Sex Chromosome Dosage Effects on X- and Y-chromosome Genes Revise Current Models of Dosage Compensation

We next harnessed our study design to test the canonical model for SCD compensation which defines four mutually-exclusive classes of sex chromosome genes that are predicted to have differing responses to changing SCD[11]: (i) pseudoautosomal region (PAR) genes, (i) Y-linked genes, (ii) X-linked genes that undergo X-chromosome inactivation (XCI), and (iv) X-linked genes that "escape" XCI (XCIE). To test this "Four Class Model" we considered all sex chromosome genes and performed unsupervised *k*-means clustering of genes by their mean expression in each of the 7 karyotype groups represented in our microarray dataset, and compared this empirically-defined grouping with that the given *a priori* by the Four Class Model (**Methods**). *k*-means clustering distinguished 5 reproducible (color-coded) clusters of SCD-sensitive sex-chromosome genes that overlapped strongly with gene groups predicted by the Four Class Model, from a large left-over cluster of 773 genes that were not consistently expressed across samples (median detection rate of 4/68 samples) and did not vary in their expression as a function of SCD (**Table 2, Fig. 2a,b , Supplementary Fig. 2a,b**).

The 5 SCD-sensitive groups of sex chromosome genes detected by k-means were: an Orange cluster of PAR genes, a Pink cluster of Y-linked genes (especially enriched for Y gametologs, odds ratio=5213, p=$1.3*10^{-15}$), a Green cluster enriched for known XCIE genes (especially X gametologs, odds ratio=335, p=$3.4*10^{-11}$), and a Yellow cluster enriched for known XCI genes. The X-linked gene responsible for initiating X-inactivation - XIST - fell into its own

Purple "cluster" (**Fig. 2b**). For all but the Orange cluster of PAR genes, observed

patterns of gene-cluster dosage sensitivity across karyotype groups deviated

from those predicted by the Four Class Model in several substantial ways (**Fig.**

2c).

Mean Expression for the Pink cluster of Y-linked genes increased in a

stepwise fashion with Y-chromosome dosage, but countered the Four Class

Model prediction by showing a sub-linear relationship with Y-chromosome count

– indicting that these Y-linked genes may be subject to active dosage

compensation. Fold-changes observed by microarray for 5/5 of these Y-linked

genes were highly replicable by qPCR in an independent sample of 401

participants with varying SCD (**Methods, Supplementary Fig. 2c).**

Four Class Model predictions were also challenged by observed

expression profiles for the Yellow and Green clusters of X-linked genes (**Table 2,**

Fig. 2c,d). Linear models for X and Y chromosome dosage effects on expression

(**Methods**) indicated that the XCI-enriched Yellow cluster was highly sensitive to

SCD ($F=47.7$, $p<2.2*10^{-16}$), and expression of genes in this cluster was

significantly *inversely* related to X-chromosome dosage at the level of both mean

cluster expression (coefficient for linear effect of X-chromosome count on

expression = -0.12, $p=3.8*10^{-15}$) and the individual expression profile of 60/66

genes within the cluster ($p<0.05$ for negative linear effect of X count on

expression). This observation indicates that increasing X copy number does not

solely involve silencing of these genes from the inactive X-chromosome, but a

further repression of their expression from the additional active X-chromosome.

Remarkably, mean expression of the XCI gene cluster was also

significantly decreased by presence of a Y-chromosome at the level of both

mean cluster expression (coefficient for linear effect of Y-chromosome count on

expression = - 0.09, p= $1.4*10^{-14}$) and expression profiles of 48/66 individual

cluster genes (p<0.05 for negative linear effect of Y count on expression). The

Green XCIE cluster manifested an inverted version of this effect whereby

increases in Y chromosome dosage were associated with increased gene

expression (p< $6.2*^{10-11}$ for mean cluster expression and p<0.05 for 23/39 cluster

genes) - providing the first evidence that Y-chromosome status can influence the

expression level of X-linked genes independently of circulating gonadal factors.

Finally, mean fold change for XCIE-cluster genes scaled sub-linearly with X-

chromosome dosage. Importantly, mean expression profiles for XCIE- and XCI-

enriched gene clusters still deviated from predictions of the Four Class Model

when analysis was restricted to genes with the highest-confidence (i.e.

independently replicated across 3 independent studies[8]) XCIE and XCI status

(respectively) in each cluster (**Fig. 2d**).

To determine the reproducibility and validity of these unexpected modes of

dosage sensitivity in XCI and XCIE gene, we first confirmed that the distinct

expression profiles for these two clusters across karyotype groups were

reproducible at the level of individual genes and samples. Indeed, unsupervised

clustering of microarray samples based on expression of XCI and XCIE cluster

genes relative to XX controls distinguished three broad karyotype groups:

females with one X-chromosome (XO), males with one X-chromosome (XY,

XYY), and individuals with extra X-chromosome (XXX, XXY, XXYY) (**Fig. 2e**).

We were also able to validate our data-driven discovery of XCI and XCIE gene

clusters against independently generated X-chromosome annotations (**Fig. 2f**),

which detail 3 distinct genomic predictors of inactivation status for X-linked

genes. Specifically, XCI cluster genes were relatively enriched (and XCIE cluster

genes relatively impoverished) for (i) having lost a Y-chromosome homolog

during evolution[12] ($X^2 = 10.9$, p=0.01), (ii) being located in older evolutionary

strata of the X-chromosome[13] ($X^2 = 22.6$, p=0.007), and (iii) bearing

heterochromatic markers[14] ($X^2 = 18.35$, p=0.0004). Finally, qPCR assays in LCLs

from an independent sample of 401 participants with varying SCD (**Methods,**

Supplementary Fig. 2c) validated the fold changes observed in microarray data

for 6/7 of the most SCD-sensitive Yellow and Green cluster genes. To

independently validate these predictions, we assayed novel karyotype groups

(XXXY, XXXXY) not used to test the original model and were able to confirm

reduction in expression with greater X-chromosome dosage (*ARAF*, *NGFRAP1*,

CXorf57, *TIMP1*), and Y-chromosome dosage effects upon expression of X-

linked genes (*NGFRAP1*, *CXorf57*, *PIM2*, *IL2RG*, *MORF4L2*) (**Methods,**

Supplementary Fig. 2d,e). Our findings update the canonical Four Class Model

of SCD compensation for specific Y-linked and X-linked genes, and expand the

list of X-linked genes capable of mediating wider phenotypic consequences of

SCD variation.

Figure 2 (next page). Data-Driven Partitioning of Sex Chromosome Genes by Dosage

Sensitivity. a) 2D Multidimensional scaling (MDS) plot of sex chromosome genes by their mean

expression profiles across all 7 SCD groups. Genes are coded by both Four Class Model and k-

means cluster grouping. **b)** Cross table showing enrichment of k-means clusters (rows) for Four

Class Model gene groups. Lower-bounds for enrichment odds-ratios are given where mean

enrichment = ∞ . **c)** Dot and line plots showing observed and predicted mean expression values

for each k-means gene cluster across karyotype groups. **d)** Close-up of observed (solid, color-

coded) vs. predicted (dashed, gray) expression profiles of Green and Yellow gene clusters.

Observed mean expression profiles counter still counter predictions when analysis is restricted to

core genes in each cluster with XCIE/XCI status that has been confirmed across three

independent reports (Balaton et al). **e)** Heatmap showing normalized (vs. XX mean) expression of

dosage sensitive genes in the XCIE and XCI k-means groups (rows, color-coded green and

yellow respectively), for each sample (columns, color coded by SCD group). **f)** Pie-charts

showing how genes within XCIE and XCI-enriched k-means clusters (green and yellow columns

respectively), display mirrored over/under-representation for three genomic features of X-linked

gene that have been linked to XCEI in prior research (i) persistence of a surviving Y-linked

homolog, (ii) location of the gene within "younger" evolutionary strata of the X-chromosome, and

(iii) presence of euchromatic rather than heterochromatic epigenetic markers.

230
231

Context-Specific Disruption of Autosomal Expression by Sex Chromosome Aneuploidy

We next leveraged the diverse SCAs represented in our study to assess

how SCD variation shapes expression on a genome-wide scale. By counting the

total number of differentially expressed genes (DEGs, **Methods**) in each SCA

group relative to its respective euploidic control (i.e XO and XXX compared with

XX; XXY, XYY, XXYY compared with XY), we detected order of magnitude

differences in DEG count amongst SCAs across a range of log2 fold change

(log2FC) cut-offs (**Fig. 3a,b**). We observed an order of magnitude increase in

DEG count with X-chromosome supernumeracy in males vs. females, which

although previously un-described, is congruent with the more severe phenotypic

consequences of X-supernumeracy in males vs. females[15]. Overall, increasing

the dosage of the sex chromosome associated with the sex of an individual (i.e.

X in females and Y in males) had a far smaller effect than other types of SCD

changes. Moreover, the ~20 DEGs seen in XXX contrasted with >2000 DEGs in

XO – revealing a profoundly asymmetric impact of X-chromosome loss vs. gain

on the transcriptome of female LCLs, which echoes the asymmetric phenotypic

severity of X-chromosome loss (Turner) vs. gain (XXX) syndromes in females[6].

To clarify the relative contribution of sex chromosome vs. autosomal

genes to observed DEG counts with changes in SCD, we calculated the

proportion of DEGs in every SCD group (comparing SCAs to their "gonadal

controls", and XY males to XX females) that fell within each of four distinct

genomic regions: autosomal, PAR, Y-linked and X-linked (**Fig. 3c**). Autosomal

genes accounted for >75% of all DEGs in females with X-monosomy (XO) and

males with X-supernumeracy (XXY, XXYY), but <30% DEGs in all other SCD

groups (**Methods**). These results reveal that SCD changes vary widely in their

capacity to disrupt genome function, and demonstrate that differential

involvement of autosomal genes is central to this variation. Moreover, associated

SCA differences in overall DEG count broadly recapitulate SCA differences in

phenotypic severity.

Figure 3 (next page). Genome-wide Effects of Sex Chromosome Dosage Variation. a-b)

Table **a** and corresponding line-plot **b** showing number of genes with significant differential

expression (after FDR correction with q<0.05) in different SCD contrasts at varying |log2 fold

change| cut-offs. Note the order-of-magnitude differences between the number of Differentially

Expressed Genes (DEGs) in XO ("removal of X from female") vs. XXY and XXYY ("addition of X

to male") vs. XYY and XXX ("addition of Y and X to male and female, respectively"). A |log2 fold

change| threshold of 0.26 (~20% change in expression) was applied to categorically define

differential expression in other analyses, by identifying the log2 fold change threshold increase

causing the greatest drop in DEG count for each karyotype group, and then averaging this value

across karyotype groups. **c)** Dot-and-line plot showing the proportion of DEGs in each karyotype

group that fell within different regions of the genome. The proportion of all genes in the genome

within each genomic region is shown for comparison. All SCD groups showed non-random DEG

distribution relative to the genome (p<2*10^-16), but DEG distributions differed significantly

between SCD groups (p<2*10^-16). XO, XXX and XXYY are distinguished from all other SCDs

examined by the large fraction of their overall DEG count that comes from autosomal genes.

a

DOSAGE CHANGE	CONTRAST	LOG2 FOLD CHANGE CUT-OFF			
		0.26	0.5	1	2
Loss of X in female	XO vs. XX	2204	469	50	7
Addition of X in male	XXY vs. XY	268	85	13	1
	XXYY vs. XY	266	93	9	2
Addition of Y in male	XYY vs. XY	34	15	0	0
Addition of X in female	XXX vs. XX	28	7	3	1

Sex Chromosome Dosage Regulates Large-Scale Gene Co-expression Networks

To provide a more comprehensive systems-level perspective on the impact of SCD on genome-wide expression patterns, we leveraged Weighted Gene Co-expression Network Analysis[16] (WGCNA, **Methods**). This analytic approach uses the correlational architecture of gene expression across a set of samples to detect sets (modules) of co-expressed genes. Using WGCNA, we identified 18 independent gene co-expression modules in our dataset (**Table 3**). We established that these modules were not artifacts of co-differential expression of genes between groups by demonstrating their robustness to removal of all group effects on gene expression by regression (**Supplementary Fig. 3a**), and after specific exclusion of XO samples (**Supplementary Fig. 3b**) given the extreme pattern of DE in this karyotype (**Fig. 3b**). We focused further analysis on modules meeting 2 independent statistical criteria after correction for multiple comparisons: (i) significant omnibus effect of SCD group on expression, (ii) significant enrichment for one or more gene ontology (GO) process/function terms (**Methods, Table 3, Fig. 4a-b**). These steps defined 8 functionally coherent and SCD-sensitive modules (Blue, Brown, Green, Purple, Red, Salmon, Tan and Turquoise). Notably, the SCD effects we observed on genome wide expression patterns appeared to be specific to shifts in sex chromosome gene dosage, as application of our analytic workflow to publically available genome-wide Illumina beadarray expression data from LCLs in patients with trisomy 21 (Down syndrome) revealed a highly dissimilar profile of genome-wide expression

change to that observed in sex chromosome trisomies (**Methods, Fig. 3c, Table**

4).

To specify SCA effects on module expression, we compared all

aneuploidy groups to their respective "gonadal controls" (**Fig. 3d**). Statistically

significant differences in modular eigengene expression were seen in XO, XXY

and XXYY groups - consistent with these karyotypes causing larger total DE

gene counts than other SCD variations (**Fig. 3a**). The largest shifts in module

expression were seen in XO, and included robust up-regulation of protein

trafficking (Turquoise), metabolism of non-coding RNA and mitochondrial ATP

synthesis (Brown), and programmed cell death (Tan) modules, alongside down-

regulation of cell cycle progression, DNA replication/chromatin organization

(Blue, Salmon), glycolysis (Purple) and responses to endoplasmic reticular stress

(Green) modules. Module DE in those with supernumerary X chromosomes on

an XY background, XXY and XXYY, involved "mirroring" of some XO effects –

i.e. *down-regulation* of protein trafficking (Turquoise) and *up-regulation* of cell-

cycle progression (Blue) modules – plus a more karyotype-specific up-regulation

of immune response pathways (Red).

The distinctive up-regulation of immune-system genes in samples of

lymphoid tissue from males carrying a supernumerary X-chromosome carries

potential clinical relevance for one of the best-established clinical phenotypes in

XXY and XXYY syndromes: a strongly (up to 18-fold) elevated risk for

autoimmune disorders (ADs) such as Systemic Lupus Erythmatosus, Sjogren

Syndrome, and Diabetes Mellitus[7]. In further support of this interpretation, we

found the Red module to be significantly enriched (p=0.01 by Fisher's Test, and

p=0.01 by gene set permutation) for a set of known AD risks compiled from

multiple large-scale Genome Wide Association Studies (GWAS, **Methods**). The

two GWAS implicated AD risk genes showing strongest connectivity within the

Red module and up-regulation in males bearing an extra X-chromosome were

CLECL1 and *ELF1* – indicating that these two genes should be prioritized for

further study in mechanisms of risk for heightened autoimmunity in XXY and

XXYY males. Collectively, these results represent the first systems-level

characterization of SCD effects on genome function, and provide convergent

evidence that increased risk for AD risk in XXY and XXYY syndrome may be

arise due to an up-regulation of immune pathways by supernumerary X-

chromosomes in male lymphoid cells.

To test for evidence of coordination between the changes in sex-

chromosome genes imparted by SCD (**Fig. 2**), and the genome-wide

transcriptomic variations detected through WGCNA (**Fig. 4a**), we asked if any

SCD-sensitive gene co-expression modules were enriched for one or more of the

5 SCD-sensitive clusters of sex chromosome genes (i.e. "PAR", "Y-linked",

"XCIE", "XCI" and the gene XIST). Four WGCNA modules - all composed of

>95% autosomal genes - showed such enrichment (**Fig. 4e**): The Turquoise and

Brown modules were enriched for XCI cluster genes, whereas the Green and

Blue modules were enriched for XCIE cluster genes. The Blue module was

unique for its additional enrichment in PAR genes, and its inclusion of XIST. We

generated network visualizations to more closely examine SCD-sensitive genes

and gene co-expression relationships within each of these four sex-chromosome

enriched WGCNA modules (**Fig 3f** Blue and **Supplementary Figure 3c-e** for

others**, Methods)**. The Blue module network highlights XIST, select PAR genes

(*SLC25A6*, *SFRS17A*) and multiple X-linked genes from X-Y gametolog pairs

(*EIF1AX*, *KDM6A* (*UTX*), *ZFX*, *PRKX*) for their high SCD-sensitivity, and shows

that these genes are closely co-expressed with multiple SCD-sensitive

autosomal genes including *ZWINT*, *TERF2IP* and *CDKN2AIP*.

Our detection of highly-organized co-expression relationships between

SCD sensitive sex-linked and autosomal genes hints at specific regulatory effects

of dosage sensitive sex chromosome genes in mediating the genome-wide

effects of SCD variation. To test this, and elucidate potential regulatory

mechanisms, we performed an unbiased transcription factor binding site (TFBS)

enrichment analysis of genes within Blue, Green, Turquoise and Brown WGCNA

modules (Methods). This analysis converged on a single TF - ZFX, encoded by

the X-linked member of an X-Y gametolog pair – as the only SCD sensitive TF

showing significant TFBS enrichment in one or more modules. Remarkably, the

gene *ZFX* was itself part of the Blue module, and ZFX binding sites were not only

enriched amongst Blue and Green module genes (increased in expression with

increasing X-chromosome dose), but also amongst Brown module genes that are

downregulated as X-chromosome dose increases (**Fig. 4g)**. To directly test if

changes in ZFX expression are sufficient to modify expression of Blue, Green or

Brown modules genes in immortalized lymphocytes, we harnessed existing

gene-expression data from murine T-lymphoblastic leukemia cells with and

without ZFX knockout[17] (GEO GSE43020). These data revealed that genes

downregulated by ZFX knockout in mice have human homologs that are

specifically and significantly over-represented in Blue (p=0.0005) and Green

(p=0.005) modules (p>0.1 for each of the other 6 WGCNA modules) – providing

experimental validation of our hypothesized regulatory role for ZFX.

Figure 4 (next page). Weighted Gene Co-expression Network Analysis of Sex Chromosome Dosage

Effects. a) Dot and line plots detailing mean expression (+/- 95% confidence intervals) by SCD group for 8

SCD-sensitive and functionally-coherent gene co-expression modules. **b)** Top 3 GO term enrichments for

each module. **c)** Heatmap showing distinct profile of module DE with a supernumerary chromosome 21 vs. a

supernumerary X-chromosome. **d)** Heatmap showing statistically significant differential expression of gene

co-expression modules between karyotype groups. **e)** Cross tabulation showing enrichment of each module

for the dosage-sensitive clusters of sex-chromosome genes detected by k-means. Lower-bounds for

enrichment odds-ratios are given where mean enrichment = ∞. **f)** Gene co-expression network for the Blue

module showing the top decile of co-expression relationships (edges) between the top decile of SCD-

sensitive genes (nodes). Nodes are positioned in a circle for ease of visualization. Node shape distinguishes

autosomal (circle) from sex chromosome (square) genes. Sex chromosome genes within the blue module

are color coded by their SCD-sensitivity grouping as per **Figure 2a** (PAR-Orange, XCIE – dark green, XIST

–purple). Larger node and gene name sizes reflect greater SCD sensitivity. Edge width indexes the strength

of co-expression between gene pairs. **g).** ZFX and its target genes from Blue, Green and Brown modules

with significant ZFX TFBS enrichment. Note that expression levels of ZFX (which increases in expression

with mounting X-chromosome dosage) are positively correlated (solid edges) with SCD sensitive genes that

are up-regulated by increasing X-chromosome dose (Blue and Green modules), but negatively correlated

(dashed edges) with genes that are down-regulated by increasing X-chromosome dose (Brown module).

DISCUSSION

In conclusion, our study – which systematically examined gene expression data from over 450 individuals representing a total of 9 different sex chromosome karyotypes - yields several new insights into sex chromosome biology with consequences for basic and clinical science. First, our discovery and validation of X-linked genes that are upregulated by reducing X-chromosome count – so that their expression is elevated in XO vs. XX for example - overturns classical models of sex chromosome dosage compensation in mammals, and signals the need to revise current theories regarding which subsets of sex chromosome genes can contribute to sex and SCA-biased phenotypes[18]. Our findings also challenge classical models of sex-chromosome biology by identifying X-linked genes that vary in their expression as a function of Y–chromosome dosage – indicating that the phenotypic effects of normative and aneuploidic variations in Y-chromosome dose could theoretically be mediated by altered expression of X-linked genes. Moreover, the discovery of Y chromosome dosage effects on X-linked gene expression provides novel routes for competition between maternally and paternally inherited genes beyond the previously described mechanisms of parental imprinting and genomic conflict– with consequences for our mechanistic understanding of sex-biased evolution and disease[19].

Beyond their theoretical implications, our data help to pinpoint specific genes that are likely to play key roles in mediating sex chromosome dosage effects on wider genome function. Specifically, we establish that a distinctive

group of sex-linked genes - notable for their evolutionary preservation as X-Y

gametolog pairs across multiple species, and the breadth of their tissue

expression in humans[10] – are further distinguished from other sex-linked genes

by their exquisite sensitivity to SCD, and exceptionally close co-expression with

SCD-sensitive autosomal genes. These results add critical evidence in support of

the idea that X-Y gametologs play a key role in mediating SCD effects on wider

genome function. In convergent support of this idea we show that (i) multiple

SCD-sensitive modules of co-expressed autosomal genes are enriched with

TFBS for an X-linked TF from the highly dosage sensitive *ZFX-ZFY* gemetolog

pair, and (ii) ZFX deletion causes targeted gene expression changes in such

modules.

Gene co-expression analysis also reveal the diverse domains of cellular

function that are sensitive to SCD – spanning cell cycle regulation, protein

trafficking and energy metabolism. These effects appear to be specific to shifts in

SCD as they are not induced by trisomy of chromosome 21. Furthermore, gene

co-expression analysis of SCD effects dissects out specific immune activation

pathways that are upregulated by supernumerary X-chromosomes in males, and

enriched for genes known to confer risk for autoimmune disorders that

overrepresented amongst males bearing an extra X-chromosome. Thus, we

report coordinated genomic response to SCD that could potentially explain

observed patterns of disease risk in SCA. Collectively, these novel insights serve

to refine current models of sex-chromosome biology, and advance our

understanding of genomic pathways through which sex chromosomes can shape

phenotypic variation in health, and sex chromosome aneuploidy.

MATERIALS AND METHODS

Acquisition and preparation of biosamples

RNA was extracted by standard methods (Qiagen, MD, USA) from

lymphoblastoid cell lines (LCLs) for 469 participants recruited through studies of

SCA at the National Institute of Health Intramural Research Program, and

Thomas Jefferson University [20]. All participants with X/Y-aneuploidy were non-

mosaic, and stability of karyotype across LCL derivation was confirmed by

fluorescent in situ hybridization in a randomly selected subset of samples used

for microarray analysis. Sixty-eight participants provided RNA samples for

microarray analyses (12 XO, 10 XX, 9 XXX, 10 XY, 8 XXY, 10 XYY, 9 XXYY),

and 401 participants provided RNA samples for a separate qPCR

validation/extension study (3 XO, 145 XX, 22 XXX, 146 XY, 34 XXY, 16 XYY, 17

XXYY, 8 XXXY, 10 XXXXY). The microarray and qPCR samples were fully

independent of each other (biological replicates), with the exception of 3 XO

participants in the microarray study, who each also provided a separate LCL

sample for the qPCR study (**Table 1**).

Microarray data preparation, differential expression analysis, annotation

and probe selection

Gene expression was profiled using the Illumina HT-12 v4 Expression

BeadChip Kit (Illumina Inc, San Diego, CA). Expression data were quantile

normalized across arrays and log2 transformed using the *limma* package in R[21].

For each of 47323 probes, we estimated mean expression by karyotype group,

and log2 fold change in gene expression for each unique pairwise group contrast

between karyotype groups (**Fig. 1a**), along with their associated false-discover-

rate (FDR) corrected p-values. For each pairwise karyotype group comparison,

we identified probes with significant log2 fold-changes that survived FDR

correction for multiple comparisons across all 47323 probes with q (the expected

proportion of falsely rejected nulls) set at 0.05. We also calculated a single

summary estimate of SCD effects for each probe, by calculating the proportion of

variance (r^2) in probe expression that was accounted for by the 7-level factor of

SCD group.

All 47323 microarray probes were annotated using both the vendor

manifest file and an independently published re-annotation that assigns a quality

rating to each probe based on the specificity of its alignment to the purported

transcript target [22]. We filtered for all probes with "perfect" or "good" quality

alignment to a known gene according to this reannotation, and then used the

collapseRows function from the WGCNA[23] package in R (with default settings), to

select one probe per gene. These steps resulted in high-quality measures of

expression and estimates of differential expression for 19984 autosomal and 894

sex-chromosome genes in each of 68 independent samples from 7 different

karyotype groups.

To select a log2 threshold for use in categorical definition of differentially

expressed genes (DEGs), we estimated DEG count across a range of absolute

log2 fold-change cut-offs for 6 contrast of primary interest: karyotypically normal

males vs. females (i.e. XY vs. XX), and each SCA group vs. its respective

"gonadal control" (i.e XX was the control for XO and XXX groups / XY was the

control for XXY, XYY and XXYY). An absolute log2 fold change of 0.26

(equivalent to a ~20% increase/decrease in expression) was empirically selected

as the cut-off to define differential expression by (i) separately identifying the

increase in log2FC threshold that cause the greatest drop in DEG count for each

SCA group, (ii) averaging these log2FC thresholds across all 5 SCA groups.

Identifying Genes Showing Significant Differential Expression Across All

Sampled Changes in X- and Y-Chromosome Count

The 21 unique pairwise karyotype group comparisons in our microarray

dataset included 15 contrasts involving a disparity in X-chromosome count, and

16 contrasts involving a disparity in Y-chromosome count (**Fig. 1a**). Using the

empirically-defined |log2 fold change| cut-off of 0.26 (see above), we screened all

20878 genes for evidence of significant differential expression across all

instances of X- or Y-chromosome disparity.

Comparing SCD Sensitivity of Gametolog vs. non-Gametolog Sex-Linked Genes

Fourteen of 16 established[9] X-Y gametolog gene pairs were represented in our microarray dataset. To compare the SCD sensitivity of this gene set to that of non-gametolog sex-linked genes by we first quantified the mean effect of SCD group on gene expression within the gametolog gene by averaging gene-wise r-squared values for the effect of SCD group on expression. We then determined the centile of this observed gene set mean r-squared against a distribution of r-squared values for 10,000 similarly sized sets of randomly samples non-gametolog sex-linked genes (**Fig. 1d**). This procedure was conducted separately for X- and Y-chromosomes.

A Priori Assignment of Sex Chromosome Genes to Four Class Model Categories

PAR genes were defined as those lying distal to the PAR1 and PAR2 boundaries specified in hg18 build of the human genome. Y-linked and X-linked genes were defined as those lying proximal to these PAR boundaries on the Y- and X-chromosome respectively. X-linked genes were assigned to XCIE and XCI using consensus classifications from a systematic integration[8] of XCI calls from 3 large-scale assays: expression from the inactivated human X-chromosome in 9 hybrid human-mouse cell lines[24], allelic-imbalance analysis of expression data in cell-lines from females with skewed X-inactivation[25], and X-chromosome methylation data from microarray[26]. According to the XCI categories of this

consensus report we classified X-linked genes as X-inactivated ("Subject" or

"Mostly Subject" categories), X-escape ("Escape" or "Mostly Escape" categories),

or X-other (all other intermediate categories).

Clustering of Sex Chromosome Genes by Dosage Sensitivity

For all 894 sex chromosome genes within our dataset we calculated the

mean fold-change per SCD group relative to mean expression across all SCD

groups. The resulting 894 by 7 matrix was submitted to k-means clustering

across a range of k-values using the *kmeans* function in R with nstart and

iter.max set at 100. Visual inspection of a scree plot of mean within partition sum-

of-squared residuals against k indicated an optimal 6-cluster solution

(**Supplementary Fig. 2a**). The largest of these 6 clusters (Gray cluster) gathered

genes with low or undetectable expression levels across all samples, and was

excluded from further analysis.

Reproducibility of 6 cluster solution was established using a bootstrap

method whereby individuals were randomly drawn (with replacement) from each

SCD group within our microarray dataset to derive 1000 bootstrap sets of 68

samples. k-means clustering was repeated for each of these 1000 sets to define

a 6-cluster solution in each draw (**Supplementary Fig. 2b**). Consistency of

clustering was quantified for each gene as the proportion of bootstrap draws in

which it was assigned to the same cluster as it had been in the original sample.

The median consistency score for cluster designation was >93% for all 5 clusters

of SCD-sensitive sex chromosome genes.

The observed grouping of sex chromosome genes from k-mean

clustering, was compared with the predicted Four Class Model groupings using

two-tailed Fishers tests for all potential cluster-grouping combinations (**Fig. 2b**).

Modelling X- and Y-chromosome Dosage Effects on Expression of Sex

Chromosome Gene Clusters

We used the following linear models to estimate the combined influence of

X and Y chromosome dosage in cluster and gene-level expression of Yellow

(XCI enriched) and Green (XCIE enriched) gene clusters:

Expression $\sim \beta_0$ (intercept) $+ \beta_1(X\_count) + \beta_2(Y\_count) + error$

We computed p-values for comparisons of both β_1 and β_2 coefficient

estimates against the null (0), and used these to test for significant directional

effects of sex chromosome dosage on the mean expression of each gene

cluster, as well the expression of individual genes within each cluster.

Aligning Sex Chromosome Expression, Epigenetic and Evolutionary Data

We validated our data-driven clustering of X-linked genes into Yellow (XCI

enriched) and Green (XCIE enriched) groups, by overlapping the genomic

coordinates of gene probes with segmentations of the X-chromosome according

to (i) "chromatin states" defined by computational analysis of coordinated

changes in 10 distinct chromatin marks in LCLs [14], (ii) "evolutionary strata"

reflecting staged loss of recombination between the X- and Y-chromosome [13].

Overlaps of our probe coordinate with these two annotations were defined using

the GenomicRanges package in R. As a third validation we also aligned our

clustering of X-lined genes with a previously published annotation of X-linked

genes according to whether their corresponding ancestral Y-linked homologue

has been lost, converted to a pseudogene or maintained [8]. Non-random

associations between these three annotations and Yellow vs. Green k-means

cluster membership were assessed using Chi-squared tests.

Comparison of DEG Count and Genomic Distribution Across SCA Groups

Total DEG counts were compared across SCD groups across a range of

log 2 fold change cut-offs as described above and reported in **Fig 3 a.b**. To test

for non-random distribution of DEGs across the genome in each SCD group **(Fig.**

3c), we compared observed DEG counts across 4 genomic regions - autosomal,

PAR, Y-linked and X-linked - to the background distribution of total gene counts

across these regions using the prop.test function in R. All SCD groups showed a

high non-random distribution of DEGs across the genome – reflecting preferential

involvement of sex chromosome genes ($p < 7.2 * 10^{-13}$).

Quantitative rtPCR validation of Differentially-Expressed Genes in

Microarray

Selecting genes of interest: For selected genes showing significant differential

expression between karyotype groups in our core sample, we used qPCR to

validate and extent observed fold-changes in an independent sample of 401

participants representing all the karyotypes in our core sample plus two

additional SCAs: XXXY, and XXXXY. For any given differential expression

analysis with microarray data, we selected genes for qPCR validation by

identifying which genes showed the three largest absolute fold-changes on

microarray in each relevant group contrast, and taking the union of these gene

lists.

Fluidigm qPCR protocol: Reverse Transcription reaction was performed using

RT2 HT First Strand Kit (QIAGEN, 330411) with 1000 ng RNA input per sample.

One-tenth of cDNA was preamplified using RT2 Microfluidics qPCR Reagent

system (QIAGEN, 330431) in combination with custom RT2 PreAmp pathway

primer mix Format containing 94 RT2 primer assays. Fourteen cycles of

preamplification were performed using the manufacturer recommended

preamplification protocol. Amplified cDNA was diluted 5-fold using RNase-free

water and assessed in real-time PCR using the RT2 Micrifluidics EvaGreen

qPCR Master mix and a Custom RT2 profiler PCR array PCR Array containing

96 assays, including selected DEGs of interest, housekeeping genes, reverse-

transcription controls, and positive PCR control. Real-time PCR was performed

on a Fluidigm BioMark HD (Fluidigm, San Francisco, US) using the RT2 cycling

program for the Fluidigm BioMark, which consists of an initial thermal mix stage

(50°C for 2 minutes, 70°C for 30 minutes, and 25°C for 10 minutes) followed by a

hot start at 95°C for 10 minutes and 40 cycles of 94°C for 15 seconds, and 60°C

for 60 seconds. For data processing, an assay with Ct > 23 was deemed to be

not expressed.

Differential Expression Analysis of qPCR data: For data analysis, the

ΔΔCtmethod of relative quantification was used[27]. The Ct values used for

calculating the fold changes were normalized using averaged expression of the

two housekeeping genes ACTB and B2M, which were not differentially

expressed across groups in either microarray or rtPCR data. All unique pairwise

group differences in expression were modeled using the limma R package with

identical setting to those used in analysis of microarray data (see above).

Validation and Extension of Microarray Results Using qPCR Results: All 21

unique pairwise SCD group contrasts in our microarray sample could be

reproduced in the independent qPCR dataset. We used the correlation in log 2

fold-change across these 21 contrasts to quantify the degree of agreement

between qPCR and microarray findings (**Supplementary Fig. 1a and 2d**). The

qPCR dataset also included two SCD groups that were not represented in the

microarray dataset – XXXY and XXXXY – allowing for a total of 15 novel pairwise

SCD group contrasts ("XO-XXXY", "XO-XXXXY", "XXXY-XX", "XXXXY-XX",

"XXX-XXXY",   "XXX-XXXXY", "XXXY-XY",   "XXXXY-XY",   "XXY-XXXY",

"XXY-XXXXY", "XYY-XXXY", "XYY-XXXXY", "XXYY-XXXY", "XXYY-XXXXY",

"XXXY-XXXXY") sampling diverse disparities of X- and Y-chromosome dosage.

These novel contrasts were used as a further test for the validity and

reproducibility of our microarray findings. Each of the 15 novel pairwise SCD

group contrasts was coded according to three effects of interest: difference in X-

chromosome count, difference in Y-chromosome count, and difference in Y-

chromosome count given identical X-chromosome count. These coded SCD

disparities were then correlated with observed fold-changes in the qPCR dataset

for two gene sets of interest derived from microarray analyses: (i) the 10 sex-

linked genes with "obligatory" SCD-sensitivity (**Supplementary Fig. 1b**), (ii) X-

linked genes from the "Yellow" and "Green" k-means clusters which showed fold-

changes in microarray data that violated expectations of the classical Four Class

Model (**Supplementary Fig. 2e,f**).

Weighted Gene Co-expression Network Analysis (WGCNA)

Defining Gene Co-expression Modules: Gene co-expression modules were

generated using the R package Weighted Gene Co-expression Network Analysis

(WGCNA). Briefly, this involved first calculating the Pearson correlation

coefficient between all 20978 genes across all 68 samples in our study. This

correlation matrix was transformed using a signed power adjacency function with

a threshold power of 12 (selected based on fit to scale-free topology), and then

converted into Topological Overlap Matrix (TOM) by modifying the correlation

between each pair of genes using a measure of the similarity in their respective

correlations with all other genes[28]. The resulting TOM was then converted to a

distance matrix by subtraction from 1, and used to generate a dendrogram for

clustering genes into modules. Gene modules were defined using the Dynamic

Hybrid cutree function[29] [with the following parameter settings: deepSplit (control

over sensitivity of module detection to module splitting) = 2, mergeCutHeight

(distance below which modules are merged)= 0.25, minimum module size=30)].

Given the large number of genes included in our analyses, we implemented

module detection using the "blockwise" WGCNA algorithm, which starts with a

computationally inexpensive method to assort genes into smaller co-expression

blocks, and then completes the above steps within each block before merging

module designations across blocks. This implementation of WGCNA defined 18

mutually exclusive co-expression gene modules within our data, which ranged

from 45 to 1393 genes in size, and a left-over group of 14630 genes without

module membership (**Table 3**). The expression of each module was summarized

as a module eigengene value (ME: the right singular vector of standardized

expression values for genes in that module) in every sample. These ME values

were used to determine differential expression of modules across (omnibus F-

tests) and between (T-tests) SCD groups, as well as module co-expression

across samples (Pearson correlation coefficient).

Further characterizing gene co-expression modules: We used module

preservation analysis to establish that our defined co-expression modules were

not dominated by (i) the large number of DEGs induced by X-monosomy (using

expression data excluding XO samples), or (ii) other SCD group differences in

mean expression levels (using expression data after residualization for the

effects of SCD group and re-centering at a common mean). All modules showed

high reproducibility based on a module-specific $Z_{summary}$ scores derived by

comparing observed modular connectivity and density metrics with null values

generated by 200 permutations of gene-level module membership[30]. We focused

further characterization of modules which passed two independent statistical

criteria; (i) SCD sensitivity - quantified using F-tests for the omnibus effects of

karyotyope group on modular expression quantified as the ME, (ii) functional

coherence as inferred by analysis of modular gene ontology term enrichments

using GO elite[31], and GOrilla[32].

Testing for enrichment of autoimmune disorder risk genes in WGCNA modules:

A large-scale records-based study was used to define 10 Autoimmune Disorder

(ADs) with clearly elevated prevalence rates in XXY vs. XY males[7], 9 of which

were represented in the largest available catalog of Genome Wide Association

Study (GWAS) findings (https://www.ebi.ac.uk/gwas/): Diabetes Mellitus type 1,

Multiple Sclerosis, Autoimmune Hypothyroidism, Psoriasis, Rheumatoid Arthritis,

Sjogren's Syndrome, Systemic Lupus Erythematosus, Ulcerative Colitis, and

Coeliac Disease. A total of 495 genes within our microarray sample were

annotated for showing a significant association in GWAS with one or more of

these 9 AD conditions. Overrepresentation of this AD gene set in the XXY

upregulated Red gene co-expression module was tested for using both Fisher's

exact test (p=0.01), and by comparing the observed representation of AD genes

against a null distribution generated by 10,000 random gene samples of equal

size to the red module.

Testing for patterned enrichment of dosage sensitive sex chromosome genes in

WGCNA modules: We tested if any of the 8 SCD-sensitive and functionally

enriched WGCNA modules showed enrichment for the previously derived k-

means clusters of dosage sensitive sex chromosome genes (**Fig. 2**) by applying

two-tailed Fishers tests to all pairwise module-cluster combinations (**Fig. 4 e**). All

observed associations survived Bonferroni correction for multiple comparisons.

Module Visualization: WGCNA co-expression modules were visualized by

selecting genes within the top decile of SCD-sensitivity (indexed using r-squared

for proportion of expression variance explained by group), and edges (co-

expression links between genes) in the top decile of edge strengths. All

visualizations were constructed using the igraph R package in R.

Transcription factor binding site analyses: Transcription factor binding site

(TFBS) enrichment analysis was performed each of the 4 SCD-sensitive

WGCNA modules - Blue, Green, Turquoise and Brown - that were enriched for

inclusion of gene from one or more of the 5 SCD-sensitive clusters of sex

chromosome genes. In each module, we scanned canonical promoter regions

(1000bp upstream of the transcription start site) for the top 500 genes with

strongest intramodular "connectivity" (based on kME - the magnitude of each

gene's coexpression with its module's eigengene). Next we utilized TFBS

position weight matrices (PWMs) from JASPAR database (205 non-redundant

and experimentally defined motifs)[33] to examine the enrichment for

corresponding TFBS within each module. For TFBS enrichment all the modules

were scanned with each PWMs using Clover algorithmhansen[34]. To compute the

enrichment analysis, we utilized three different background datasets (1000 bp

sequences upstream of all human genes, human CpG islands and human

chromosome 20 sequence). To increase confidence in the enrichment analyses,

we considered TFBS to be over-represented based on the P-values (<0.05)

obtained relative to all the three corresponding background datasets.

Enrichment of SCD sensitive modules for genes with DE due to experimental

ZFX knockout. To provide an orthogonal experimental test for evidence of a

regulatory role for ZFX within Blue, Green or Brown WGCNA modules, we used

a list of genes with significantly decreased expression due to ZFX knockout in

murine lymphocytes[17]. Human homologs were found for these genes

(http://www.informatics.jax.org/downloads/reports/index.html), and two-tailed

Fishers Tests were used to assess if these human genes were significantly

enriched/impoverished in any of the 8 SCD sensitive WGCNA modules.

759 Comparison of Autosomal Gene Fold-Change in SCA and Down Syndrome

The transcriptomic effects on Trisomy 21 (T21) were characterized in

LCLs by passing a publically available Illumina microarray gene expression

dataset (GEO, Accession number GSE34458) through an identical analytic

pipeline to that used in characterizing genome-wide fold changes in our SCA

sample (see above). We first independently confirmed the previously reported

finding that chromosome 21 was robustly enriched for genes showing differential

expression in this T21 data set (Chi-squared=999, p<2*10-16 for enrichment of

DEGs on chromosome 21) – buttressing use of these data to assess

transcriptomic effects of T21. We examined overlaps in genome-wide expression

change between T21 and the three sex chromosome trisomes in our samples

(XXY, XYY and XXX) using 17671 genes with complete expression data in both

microarray datasets (after exclusion of genes on chromosomes X, Y and 21).

We tested for, and failed to find any evidence of significant overlap in DEGs

using Chi-squared tests (**Table 4**). To test if T21 showed a similar shift in gene

co-expression modules to sex chromosome trisomies, we used the designation

of genes to modules in the SCA sample to recalculate module Eigengenes. We

then calculated MR fold changes for T21 and three SCA trisomies (XXX, XXY

and XYY). Trisomy of chromosome 21 was associated with a clearly distinct

profile of ME expression chance than all three of the SCA trisomies (**Fig. 4c**).

REFERENCES

1. Hughes, J. F. & Rozen, S. Genomics and genetics of human and primate y chromosomes. *Annu Rev Genomics Hum Genet* **13,** 83–108 (2012).

2. Arnold, A. P. The end of gonad-centric sex determination in mammals. *Trends Genet* **28,** 55–61 (2012).

3. Bermejo-Alvarez, P., Rizos, D., Rath, D., Lonergan, P. & Gutierrez-Adan, A. Sex determines the expression level of one third of the actively expressed genes in bovine blastocysts. *Proc. Natl. Acad. Sci. U. S. A.* **107,** 3394–3399 (2010).

4. Petropoulos, S. *et al.* Single-Cell RNA-Seq Reveals Lineage and X Chromosome Dynamics in Human Preimplantation Embryos. *Cell* **165,** 1012–1026 (2016).

5. Belling, K. *et al.* Klinefelter syndrome comorbidities linked to increased X chromosome gene dosage and altered protein interactome activity. *Hum. Mol. Genet.* **26,** 1219–1229 (2017).

6. Hong, D. S. & Reiss, A. L. Cognitive and neurological aspects of sex chromosome aneuploidies. *Lancet Neurol.* **13,** 306–318 (2014).

7. Seminog, O. O., Seminog, A. B., Yeates, D. & Goldacre, M. J. Associations between Klinefelter's syndrome and autoimmune diseases: English national record linkage studies. *Autoimmunity* **48,** 125–128 (2015).

8. Balaton, B. P., Cotton, A. M. & Brown, C. J. Derivation of consensus inactivation status for X-linked genes from genome-wide studies. *Biol. Sex Differ.* **6,** 35 (2015).

9. Skaletsky, H. *et al.* The male-specific region of the human Y chromosome is a mosaic of discrete sequence classes. *Nature* **423,** 825–37 (2003).

10. Bellott, D. W. *et al.* Mammalian Y chromosomes retain widely expressed dosage-sensitive regulators. *Nature* **508,** 494–499 (2014).

11. Deng, X., Berletch, J. B., Nguyen, D. K. & Disteche, C. M. X chromosome regulation: diverse patterns in development, tissues and disease. *Nat. Rev. Genet.* **15,** 367–378 (2014).

12. Wilson Sayres, M. A. & Makova, K. D. Gene survival and death on the human Y chromosome. *Mol. Biol. Evol.* **30,** 781–787 (2013).

13. Pandey, R. S., Wilson Sayres, M. A. & Azad, R. K. Detecting evolutionary strata on the human x chromosome in the absence of gametologous y-linked sequences. *Genome Biol. Evol.* **5,** 1863–1871 (2013).

14. Ernst, J. *et al.* Mapping and analysis of chromatin state dynamics in nine human cell types. *Nature* **473,** 43–49 (2011).

15. Aksglaede, L. & Juul, A. Testicular function and fertility in men with Klinefelter syndrome: a review. *Eur. J. Endocrinol. Eur. Fed. Endocr. Soc.* **168,** R67-76 (2013).

16. Parikshak, N. N., Gandal, M. J. & Geschwind, D. H. Systems biology and gene networks in neurodevelopmental and neurodegenerative disorders. *Nat. Rev. Genet.* **16,** 441–458 (2015).

17. Weisberg, S. P. *et al.* ZFX controls propagation and prevents differentiation of acute T-lymphoblastic and myeloid leukemia. *Cell Rep.* **6,** 528–540 (2014).

18. Disteche, C. M. Dosage compensation of the sex chromosomes and autosomes. *Semin. Cell Dev. Biol.* **56,** 9–18 (2016).

19. Cocquet, J. *et al.* A genetic basis for a postmeiotic x versus y chromosome intragenomic conflict in the mouse. *PLoS Genet* **8,** e1002900 (2012).

20. Zinn, A. R. *et al.* A Turner syndrome neurocognitive phenotype maps to Xp22.3. *Behav. Brain Funct. BBF* **3,** 24 (2007).

21. Ritchie, M. E. *et al.* limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res.* **43,** e47 (2015).

22. Barbosa-Morais, N. L. *et al.* A re-annotation pipeline for Illumina BeadArrays: improving the interpretation of gene expression data. *Nucleic Acids Res.* **38,** e17 (2010).

23. Langfelder, P. & Horvath, S. WGCNA: an R package for weighted correlation network analysis. *BMC Bioinformatics* **9,** 559 (2008).

24. Carrel, L. & Willard, H. F. X-inactivation profile reveals extensive variability in X-linked gene expression in females. *Nature* **434,** 400–4 (2005).

25. Cotton, A. M. *et al.* Analysis of expressed SNPs identifies variable extents of expression from the human inactive X chromosome. *Genome Biol.* **14,** R122 (2013).

26. Cotton, A. M. *et al.* Landscape of DNA methylation on the X chromosome reflects CpG density, functional chromatin state and X-chromosome inactivation. *Hum. Mol. Genet.* **24,** 1528–1539 (2015).

27. Schmittgen, T. D. & Livak, K. J. Analyzing real-time PCR data by the comparative C(T) method. *Nat. Protoc.* **3,** 1101–1108 (2008).

28. Zhang, B. & Horvath, S. A general framework for weighted gene co-expression network analysis. *Stat. Appl. Genet. Mol. Biol.* **4,** Article17 (2005).

29. Langfelder, P., Zhang, B. & Horvath, S. Defining clusters from a hierarchical cluster tree: the Dynamic Tree Cut package for R. *Bioinforma. Oxf. Engl.* **24,** 719–720 (2008).

30. Langfelder, P., Luo, R., Oldham, M. C. & Horvath, S. Is my network module preserved and reproducible? *PLoS Comput. Biol.* **7,** e1001057 (2011).

31. Zambon, A. C. *et al.* GO-Elite: a flexible solution for pathway and ontology over-representation. *Bioinforma. Oxf. Engl.* **28,** 2209–2210 (2012).

32. Eden, E., Navon, R., Steinfeld, I., Lipson, D. & Yakhini, Z. GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists. *BMC Bioinformatics* **10,** 48 (2009).

33. Portales-Casamar, E. *et al.* JASPAR 2010: the greatly expanded open-access database of transcription factor binding profiles. *Nucleic Acids Res.* **38,** D105-110 (2010).

34. Frith, M. C. *et al.* Detection of functional DNA motifs via statistical over-representation. *Nucleic Acids Res.* **32,** 1372–1381 (2004).

TABLE LEGENDS (Tables provided as individual .xlsx files due to size)

Table 1. Sample Characteristics for Core Microarray Dataset (n=68) and PCR Validation Sample (n=401). Number of samples by karyotype group, with details of age and self-reported "race" distributions by group. *XO samples in PCR validation study are an independent sample of cells drawn from 3 of the 12 XO cell-lines used in the core microarray study (i.e. technical replicates). All other samples used in the PCR validation study were drawn from a separate set of participants to those included in the microarray study (i.e. biological replicates).

Table 2. Data-Driven Grouping of Sex Chromosome Genes by Dosage Sensitivity. Each row relates to one of the 5 distinct gene groups detected by k-means clustering according to mean expression across karyotype groups. Details are provided group size, constituent genes, and observed profile of SCD Sensitivity. Heatmap colors in fold-change (FC) columns index the magnitude (color intensity) and direction of each k-mean cluster's change in mean expression (yellow - increased, blue- decreased) for selected pairwise SCD group contrasts. Note how (i) the Yellow cluster enriched for XCI genes is less expressed in groups with greater X-chromosome count, and (ii) Yellow and Green clusters enriched for XCI and XCIE genes respectively are both differentially expressed between groups that differ in Y-chromosome status, but have identical X-chromosome count.

Table 3. Characteristics of Gene-Coexpression Modules Generated by WGCNA. For all 19 modules defined by WGCNA, we provide information regarding: module size; "top" module genes [defined by strength of correlated expression with module eigengene (ME)]; proportion variance in module expression explained by ME; ME correlation with other ME of all other modules; F-test for effect of SCD on ME variance; results of t-tests for selected group differences in ME expression (bold cells survive Bonferroni correction for # modules); significant GO term enrichment by GOelite and GOrilla; binary statement regarding whether module shows both significant SCD sensitivity and significant GO terms enrichment

Table 4. Cross-tabulations and associated Chi-squared tests for overlap in differentially expressed genes between trisomy 21 and the 3 sex-chromosome trisomies in our sample. Note, these calculations were made after removal of genes located on sex chromosomes, or chromosome 21. For this comparison, differential expression was defined as a statistically significant fold change in expression of any magnitude that survived FDR correction for multiple comparisons at q=0.05 This liberal fold-change cut-off was applied given the to accommodate the very small number of DEGs seen in XXX